SCHEMBL4282800

SCHEMBL4282800

COCCOCCn1ccc2ncnc(Cl)c21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.38
ERBB2 P04626 5/20 0.38
ERBB3 P21860 5/20 0.38
ERBB4 Q15303 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.36
LMNA P02545 1/20 0.36
FGFR1 P11362 3/20 0.36
FGFR4 P22455 1/20 0.36
KDR P35968 2/20 0.35
GRIN2B Q13224 1/20 0.34
MAPT P10636 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
PKM P14618 1/20 0.33
NFKB1 P19838 1/20 0.33
RAB9A P51151 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
KMT2A Q03164 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3506358 0.91 FGFR1 (0.39) EGFRERBB2ERBB3ERBB4SMN1; SMN2
SCHEMBL2748396 0.86 FGFR1 (0.37) EGFRERBB2ERBB3ERBB4SMN1; SMN2
SCHEMBL7028699 0.80 FGFR1 (0.35) SMN1; SMN2LMNAFGFR1FGFR4MAPT
SCHEMBL2749135 0.79 FGFR1 (0.40) EGFRERBB2ERBB3ERBB4FGFR1
SCHEMBL27664616 0.78 TLR8 (0.44) SMN1; SMN2LMNAFGFR1FGFR4GRIN2B
SCHEMBL3403862 0.77 FGFR1 (0.40) EGFRERBB2ERBB3ERBB4FGFR1
SCHEMBL2748299 0.77 TDP1 (0.40) EGFRERBB2ERBB3ERBB4SMN1; SMN2
SCHEMBL2748523 0.76 FGFR1 (0.42) EGFRERBB2ERBB3ERBB4FGFR1
SCHEMBL2748776 0.76 FGFR1 (0.40) EGFRERBB2ERBB3ERBB4FGFR1
SCHEMBL2749352 0.76 EGFR (0.44) EGFRERBB2ERBB3ERBB4FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137580-A1 Fused Heterocyclic Derivatives and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137580-A1 Fused Heterocyclic Derivatives and Use Thereof TIE1, KDR, FLT1 EGFR 20/4885ERBB2 8/4885ERBB3 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.